Overview

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Aztreonam